Inflammatory Bowel Diseases最新文献

{"title":"Efficacy and Safety of Upadacitinib in a Case of Pediatric Acute Severe Ulcerative Colitis and Immune Thrombocytopenia.","authors":"Benedetta Bocchini, Massimo Martinelli, Caterina Strisciuglio, Pio Stellato, Maria Teresa Fioretti, Annamaria Staiano, Erasmo Miele","doi":"10.1093/ibd/izaf139","DOIUrl":"https://doi.org/10.1093/ibd/izaf139","url":null,"abstract":"","PeriodicalId":13623,"journal":{"name":"Inflammatory Bowel Diseases","volume":" ","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144540072","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"An Acute Onset Sweet Syndrome After First Vedolizumab Dose in Crohn's Disease.","authors":"Desmond Patrick, Lubna Siddiq, Aaron Boyce","doi":"10.1093/ibd/izaf122","DOIUrl":"https://doi.org/10.1093/ibd/izaf122","url":null,"abstract":"","PeriodicalId":13623,"journal":{"name":"Inflammatory Bowel Diseases","volume":" ","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144540070","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Fecal Calprotectin is a Useful Biomarker for Defining Small Bowel Endoscopic Remission in Crohn's Disease Without Active Colonic Lesions: A Prospective Multicenter Study from the IBD-Quality Team.","authors":"Teruyuki Takeda, Nobuaki Nishimata, Shin Fujioka, Nanae Tsuruoka, Yoki Furuta, Haruhiko Takahashi, Fukunori Kinjo, Shuji Kanmura, Shojiro Yamamoto, Ryosuke Sakemi, Shinya Ashizuka, Kozue Kakizoe, Takashi Hisabe, Motohiro Esaki, Hisatomi Arima, Fumihito Hirai","doi":"10.1093/ibd/izaf138","DOIUrl":"https://doi.org/10.1093/ibd/izaf138","url":null,"abstract":"<p><strong>Background: </strong>Conflicting reports exist on the correlation of fecal calprotectin (FC), with the endoscopic severity of small bowel lesions of Crohn's disease (CD). This study aimed to analyze the correlation between FC and small bowel lesions observed by small bowel capsule endoscopy (CE).</p><p><strong>Methods: </strong>This prospective multicenter study involved patients aged 16 to < 60 years with CD of ileal or ileocolonic types without a history of intestinal resection. The participants underwent CE, ileocolonoscopy, and FC within a period of 1 month. Patients with active colonic lesions were excluded. Endoscopic remission (ER) was defined as the absence of an ulcer (≥ 5 mm). The primary endpoint was to determine whether FC could be used to define ER of small bowel lesions in patients with CD. The secondary endpoints were the correlation of CE activity and FC.</p><p><strong>Results: </strong>The study involved 49 patients. The correlation between FC and Lewis score was positive with r = 0.436 (P = .002). The receiver operating characteristic curve constructed for ER and FC had an area under the curve of 0.828 (95% confidence interval, 0.694-0.962; P < .001). The cutoff FC for ER was calculated to be 175 μg/g. The correlation between FC and Capsule Endoscopy Crohn's Disease Activity Index was positive with r = 0.542 (P < .001).</p><p><strong>Conclusions: </strong>This study revealed a correlation between small bowel CE activity and FC. Under this condition, small bowel ER can be defined as an FC level of < 175 μg/g, and FC was suggested to be a useful biomarker for monitoring small bowel lesions during the application of treat-to-target strategies.</p>","PeriodicalId":13623,"journal":{"name":"Inflammatory Bowel Diseases","volume":" ","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144527806","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Validation of the Modified Multiplier of SES-CD (MM-SES-CD) to Predict Endoscopic Healing in Crohn's Disease: A Post Hoc Analysis of the SEAVUE Trial.","authors":"Dhruv Ahuja, Sama Anvari, Emily C L Wong, Parambir Dulai, John K Marshall, Vipul Jairath, Walter Reinisch, Neeraj Narula","doi":"10.1093/ibd/izaf137","DOIUrl":"https://doi.org/10.1093/ibd/izaf137","url":null,"abstract":"<p><strong>Background: </strong>The modified multiplier of the SES-CD (MM-SES-CD) has been shown to predict future endoscopic healing (EH) in patients with Crohn's disease. The purpose of this study was to validate baseline MM-SES-CD categories of severity and determine their prognostic value for predicting 1-year EH.</p><p><strong>Methods: </strong>Participants in the SEAVUE trial (n = 386) were classified based on baseline endoscopic disease severity using MM-SES-CD cut-offs as mild (≥ 22.5 to < 31), moderate (≥ 31 to < 45), and severe (≥ 45) disease. The primary outcome was achieving 1-year endoscopic healing (EH) as measured by the MM-SES-CD score (< 22.5). Secondary outcomes included clinical and biochemical remission at 1 year based on patient-reported outcomes and fecal calprotectin (FCP)(< 250 mcg/g).</p><p><strong>Results: </strong>MM-SES-CD < 22.5 at 1 year was achieved in 62.0% of patients with baseline mild endoscopic disease, 48.6% with moderate disease, and 33.8% with severe disease (P < .001). A similar trend was observed for patient-reported outcome (PRO-2) clinical remission, which was reached in 78.9% of patients with baseline mild endoscopic disease, 72.9% of those with moderate, and 66.2% of those with severe disease (P = 0.09). The likelihood of fecal calprotectin (FCP) remission was significantly associated with baseline endoscopic disease severity (P = .008).</p><p><strong>Conclusion: </strong>Baseline MM-SES-CD-based cutoffs for endoscopic disease severity show prognostic value for the likelihood of achieving 1-year EH, PRO2 remission, and FCP remission. These findings suggest that the MM-SES-CD can be used both to measure baseline endoscopic disease severity and predict outcomes at 1 year in patients with moderate to severe CD.</p>","PeriodicalId":13623,"journal":{"name":"Inflammatory Bowel Diseases","volume":" ","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144527810","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation and Management of Glucocorticoid-Induced Adrenal Insufficiency in IBD: An Expert Opinion.","authors":"Cindy C Y Law, Rachel Sheskier, Natalia Viera-Feliciano, Andrea Delgado-Nieves, Shivani Seth, Jurij Hanžel, Christopher Ma, Jean-Frédéric Colombel, Alice C Levine, Elizabeth A Spencer","doi":"10.1093/ibd/izaf136","DOIUrl":"https://doi.org/10.1093/ibd/izaf136","url":null,"abstract":"<p><strong>Background and aims: </strong>Glucocorticoid-induced adrenal insufficiency (GC-AI) is a potentially life-threatening side effect of glucocorticoid therapy. Currently, there is no consensus on monitoring and treating GC-AI in inflammatory bowel disease (IBD) patients. This systematic review and meta-analysis aimed to determine the prevalence of GC-AI in IBD patients following glucocorticoid use. Additionally, a Delphi panel was conducted to develop evidence-based expert opinions on evaluating and managing GC-AI in IBD patients.</p><p><strong>Methods: </strong>Thirty-four articles were included in this study. Of these, 26 articles reported the prevalence of GC-AI in IBD patients. Statements were generated and rated by a panel of adult and pediatric gastroenterologists using a 1-9 scale. Statements were classified as inappropriate, uncertain, or appropriate based on the median panel rating and the degree of disagreement.</p><p><strong>Results: </strong>The prevalence of GC-AI across all studies was 26.9% (95% CI: 18.9-36.8, I2: 96%). The panel emphasized the importance of maintaining a high suspicion for GC-AI in IBD patients treated with systemic glucocorticoids and considering risk factors such as exogenous glucocorticoid use ≥4 weeks at doses ≥5 mg of prednisone-equivalent. Recommendations for initial screening and management of GC-AI are provided. The management of GC-AI in special populations, such as those in the perioperative setting is also addressed. The panel underscored the need to consider GC-AI assessment in clinical trial design.</p><p><strong>Conclusions: </strong>GC-AI is a serious, often underrecognized side effect of glucocorticoid use. This study presents expert opinions on the evaluation and management of GC-AI in IBD patients, emphasizing the need for vigilance and appropriate management strategies.</p>","PeriodicalId":13623,"journal":{"name":"Inflammatory Bowel Diseases","volume":" ","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144527805","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Oral Vancomycin as an Emerging Therapy for Inflammatory Pouch Conditions Associated With Primary Sclerosing Cholangitis.","authors":"Katie Dunleavy, Abigail Meyers, Tommaso Violante, Blake Kassmeyer, Siri A Urquhart, Nayantara Coelho-Prabhu, Laura Raffals, David Larson","doi":"10.1093/ibd/izaf117","DOIUrl":"https://doi.org/10.1093/ibd/izaf117","url":null,"abstract":"","PeriodicalId":13623,"journal":{"name":"Inflammatory Bowel Diseases","volume":" ","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144527808","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Unraveling Genetic Versus Environmental Factors Determining Disease Course in Inflammatory Bowel Diseases: A Population-Based Cohort Study in First- and Second-Generation Immigrants.","authors":"Anna-Teresa D'Hooghe, Gry Juul Poulsen, Christian Nikolai Sørensen, Parul Tandon, Nynne Nyboe Andersen, Séverine Vermeire, Bram Verstockt, Tine Jess","doi":"10.1093/ibd/izaf128","DOIUrl":"https://doi.org/10.1093/ibd/izaf128","url":null,"abstract":"<p><strong>Background: </strong>Inflammatory bowel diseases (IBD) incidence in immigrants approximates that of the host country in progressive generations but less is known about their disease outcome. We investigate how the immigrant generation affects IBD outcomes.</p><p><strong>Methods: </strong>In this population-based cohort study, the risks of first IBD-related hospitalization, first IBD-related surgery, need for advanced therapies, and perianal disease were compared between first- and second-generation immigrants (stratified into Western/non-Western) and native Danes, using Cox proportional hazard regression to estimate adjusted hazard ratios (aHRs), correcting for sex, age at IBD diagnosis, and calendar year of IBD diagnosis.</p><p><strong>Results: </strong>First-generation immigrants had lower risk of IBD-related surgery (aHRWestern 0.89; 95% confidence interval [CI] 0.75-1.05, aHRnon-Western 0.79; 95% CI, 0.67-0.92) and advanced therapy (aHRWestern 0.87; 95% CI, 0.77-0.99, aHRnon-Western 0.83; 95% CI, 0.74-0.94) than native Danes, whereas second-generation immigrants resembled native Danes. However, second-generation immigrants had higher risk of hospitalization than native Danes (aHRWestern 1.28; 95% CI, 1.05-1.55, aHRnon-Western 1.40; 95% CI, 1.28-1.54), whereas in first-generation immigrants this was only observed in non-Western ulcerative colitis patients (aHR 1.19; 95% CI, 1.08-1.32). Across both generations, non-Western immigrants had higher risk of perianal disease (Crohn's disease: aHRfirst-generation 1.55; 95% CI, 1.25-1.92; aHRsecond-generation 1.58; 95% CI, 1.25-2.01).</p><p><strong>Conclusions: </strong>Disease outcomes change across immigrant generations, pointing to environmental factors possibly impacting disease course, which needs further investigation. In contrast, non-Western immigrants were shown to have more perianal disease in both generations, suggesting a genetic susceptibility for this debilitating phenotype.</p>","PeriodicalId":13623,"journal":{"name":"Inflammatory Bowel Diseases","volume":" ","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-06-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144527809","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Fecal Microbial Community Profiling Allows Discrimination of Phenweotype and Treatment Response in Pediatric Crohn's Disease and Ulcerative Colitis-An International Meta-Analysis.","authors":"Denise Aldrian, Adam Pollio, Christoph Mayerhofer, Kay Diederen, Jonathan P Jacobs, Nikhil Pai, Jake C Szamosi, Lara Hart, Dan Turner, Federica Del Chierico, Sabrina Cardile, Zoya Grigoryan, Lea Ann Chen, Jakub Hurych, Ondrej Cinek, Carla R Taddei, Tobias Schwerd, Eytan Wine, Anne M Griffiths, Thomas Müller, Georg F Vogel","doi":"10.1093/ibd/izaf135","DOIUrl":"https://doi.org/10.1093/ibd/izaf135","url":null,"abstract":"<p><strong>Background and aims: </strong>The pathophysiology of pediatric inflammatory bowel disease (PIBD), encompassing Crohn's disease (CD) and ulcerative colitis (UC), is not entirely understood. Dysregulation of the intestinal microbiome is recognized as both a disease-driving and a potential therapeutic target. This study aimed to systematically analyze gut microbiome compositions and its applicability as a biomarker for disease progress and treatment response.</p><p><strong>Methods: </strong>Bibliographic and nucleotide databases were searched. Raw 16S-rRNA sequencing reads were subjected to a uniform downstream dada2/phyloseq pipeline to extract taxonomy, community structure, and abundance information. Patient metadata were extracted from publications, and study authors were contacted for further details if required.</p><p><strong>Results: </strong>Twenty-six studies comprising 3956 stool samples (CD 41%, UC 36%, 23% healthy) were included in the analyses. Median age of individuals was 12 (interquartile range 4). Sex distribution was comparable. Alpha diversity was reduced between the healthy and both UC and CD treatment-naïve groups (P < .001) and further reduced with increasing clinical disease activity. Beta diversity revealed altered community structure in treatment-naïve children with PIBD (P < .001). This alteration remained in patients in clinical remission (P < .001). Machine learning models discriminated between treatment-naïve patients with CD or UC with an area under the receiver operating characteristics curve (AUROC) of 98%. Microbial communities differed between patient responders versus nonresponders to treatment (P < .001). Further, microbial community profiling distinguished treatment response (eg, steroid, nutrition, or TNFα) with AUROCs of 82%-90%.</p><p><strong>Conclusions: </strong>Gut microbial community structure is substantially altered in active and inactive PIBD and may be utilized as a biomarker for differentiating PIBD subtype and predicting treatment response.</p>","PeriodicalId":13623,"journal":{"name":"Inflammatory Bowel Diseases","volume":" ","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-06-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144527807","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prostaglandins and Inflammatory Bowel Disease: From Mechanism to Clinic.","authors":"Jia-Li Huang, Wen-Tao Tan, Hong Liu","doi":"10.1093/ibd/izaf121","DOIUrl":"https://doi.org/10.1093/ibd/izaf121","url":null,"abstract":"<p><p>Inflammatory bowel disease (IBD), mainly consisting of ulcerative colitis and Crohn's disease, represents a multifaceted and chronic inflammatory disorder that has arisen as a critical public health challenge globally. The underlying mechanisms of IBD are not fully elucidated, involving a complex interaction among various elements, such as genetic predispositions, environmental factors, immune system reactions, and changes in gut microbiota. Being a lifelong disorder, IBD currently has no cure. Prostaglandins (PGs), which are derived from arachidonic acid via a series of enzymatic transformations, encompass several forms, including PGE2, PGD2, PGI2, PGF2α, and TXA2. These compounds display a diverse array of biological activities and play a key role in regulating numerous physiological and pathological phenomena, including inflammation, immune responses, cancer development, reproductive processes, cardiovascular health, and gastric mucosal defense. Within the gastrointestinal system, PGs perform various essential functions, such as preserving the mucosal barrier and modulating intestinal motility, blood circulation, and immune activities. Research indicates that PGs are crucial in the disease mechanisms related to IBD, with distinct PG types and their receptors displaying both pro-inflammatory and anti-inflammatory properties. Nevertheless, the associated signaling pathways and molecular interactions are still insufficiently investigated. As a result, therapeutic approaches focusing on PGs and the pathways contributing to their synthesis have become a primary objective in IBD treatment research. This paper intends to examine the significance of PG receptors in IBD, providing a fresh viewpoint for understanding the pathogenesis of the disease and establishing a theoretical basis for creating diagnostic tools and treatment strategies centered around PG targets to improve patient outcomes.</p>","PeriodicalId":13623,"journal":{"name":"Inflammatory Bowel Diseases","volume":" ","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144484183","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pou2af1 Deficiency Aggravates DSS-Induced Colitis via Impaired Germinal Center Responses and Altered Gut Microbiota.","authors":"Jijun Huang, Wenting Liang, Ruizhi Zhang, Yuyang Zhao, Rong Shi, Xiangming Chen, Yanling Zheng, Xiaomin Li, Donglian Liu, Haoyang Wang, Jiamin Liu, Yue Liao, Xinqi Zhang, Zhihan Jiang, Cheng Fu, Ting Huang, Xiaokang Shan, Wanlin Wang, Jin Bu, Tieli Peng, Erxia Shen","doi":"10.1093/ibd/izaf089","DOIUrl":"https://doi.org/10.1093/ibd/izaf089","url":null,"abstract":"<p><strong>Background: </strong>Bob1 plays a critical role in immune system regulation, particularly in the function of B cells. Its deficiency in the context of colitis remains underexplored. This study investigates the effects of Bob1 (Pou2af1) deficiency on colitis, particularly focusing on immune responses and gut microbiota alterations in a murine model.</p><p><strong>Methods: </strong>In this study, we employed Pou2af1 knockout (KO) and wild-type (WT) mice to investigate the role of Bob1 in dextran sodium sulfate (DSS)-induced colitis. Colitis was induced by administering 2.5% DSS in drinking water for 7 days. Mice were monitored daily for weight loss, stool consistency, and rectal bleeding to calculate the disease activity index (DAI). Colon length was measured, and colon tissues were collected for histological analysis using hematoxylin and eosin (H&E) staining. Flow cytometry was performed to assess germinal center responses as well as the proportion of T helper (Th)1 and Th17 cells in the colonic lamina propria. Metagenomic sequencing was conducted on fecal samples to evaluate gut microbiota composition.</p><p><strong>Results: </strong>Pou2af1-deficient mice exhibited significantly exacerbated colitis compared to WT mice. This was evidenced by greater weight loss, elevated disease activity index, reduced colon length, and more severe pathological changes. Immune analysis revealed an impaired germinal center response, diminished generation of IgA⁺ plasma cells, and decreased Th17 cells in the colonic lamina propria in Pou2af1-deficient mice. Additionally, microbiota analysis indicated dysbiosis in the Pou2af1-deficient group, with a notable decrease in Bacteroides species and an increase in pro-inflammatory microbes.</p><p><strong>Discussion: </strong>The findings suggest that Pou2af1 deficiency exacerbates DSS-induced colitis by impairing immune responses, particularly the germinal center reaction, and altering gut microbiota composition. These alterations contribute to increased disease severity, highlighting the importance of Pou2af1 in maintaining intestinal immune homeostasis.</p>","PeriodicalId":13623,"journal":{"name":"Inflammatory Bowel Diseases","volume":" ","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144484182","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}